Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Business

Amgen Invests $2.7 Billion in China’s BeiGene with Plans to Develop 20 Pipeline Drugs

“This strategic collaboration with BeiGene will enable Amgen to serve significantly more patients by expanding our presence in the world’s most populous country,” said Robert A. Bradway, Amgen’s chairman and chief executive officer.

November 1, 2019

2 min read

Mark Terry

Business

Amgen Closes Out Neuroscience Programs as it Focuses on Long-Term Growth Areas

Chief Financial Officer David Meline said the decision was made in order to provide the financial support to areas that will provide long-term growth for the company.

October 30, 2019

3 min read

Alex Keown

Business

Generational Priorities: What Baby Boomers, Gen-Xers and Millennials Think Makes an Ideal Employer

When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.

October 21, 2019

3 min read

Porschia Parker

Employer Resources

Employees’ Perception vs. Employers’ Reality! New Research Shows the Top 3 Areas of Opportunity

What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?

October 11, 2019

4 min read

Porschia Parker

Bio NC

BioSpace Announces the 2019 Top 30 Life Sciences Ideal Employers

According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.

September 24, 2019

1 min read

BioSpace Staff

Drug Development

Clinical Catch-Up: September 9-13

Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.

September 13, 2019

11 min read

Mark Terry

Business

Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen

Toronto Innovation Acceleration Partners, a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry.

September 12, 2019

2 min read

Biotech Beach

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS G12C Inhibitor In Larger Patient Group At WCLC 2019

Amgen announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors.

September 9, 2019

10 min read

Drug Development

Investors Apparently Not Sold on Amgen’s Lung Cancer Drug

Amgen shares dropped 4.2% in pre-market trading at good but not amazing results in an early-stage trial of AMG 510 in in patients with previously treated KRAS G12C-mutated solid tumors.

September 9, 2019

3 min read

Mark Terry

JOBS